Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epacadostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 known ✓ | P14902 | 20/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TDO2 | P48775 | 1/20 | 0.70 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epacadostat SCHEMBL18823200 | 1.00 | IDO1 (0.70) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| Epacadostat SCHEMBL145946 | 1.00 | IDO1 (0.70) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| Epacadostat SCHEMBL29608961 | 1.00 | IDO1 (0.70) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144580 | 0.94 | IDO1 (0.63) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144581 | 0.94 | IDO1 (0.63) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL19881756 | 0.91 | IDO1 (0.69) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL18844593 | 0.91 | IDO1 (0.69) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL145811 | 0.90 | IDO1 (0.70) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL145812 | 0.90 | IDO1 (0.70) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL19679829 | 0.90 | IDO1 (0.70) | IDO1CYP3A4CYP2C9TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5761 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139022-A1 | COMPOSITIONS INCLUDING TUMOR-BINDING GMCSF FUSION PROTEINS AND METHODS OF USING THE SAME TO TREAT SOLID TUMORS | UNIV OF KANSAS (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS LLC (US) | 2026-05-21 | — | — | US | claimed |
| US-12630624-B2 | Anti-IL-27 antibodies and uses thereof | Surface Oncology, LLC (US) | 2026-05-19 | — | — | US | claimed |
| CN-122031417-A | Pharmaceutical composition for enhancing immunotherapeutic effect of colon cancer | 天津市肿瘤医院（天津医科大学肿瘤医院） | 2026-05-15 | — | — | CN | claimed |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-12 | — | — | US | claimed |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | THE UNIVERSITY OF CHICAGO (US) | 2026-02-19 | — | — | US | claimed |
| US-12551581-B2 | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | GALERA LABS, LLC (US) | 2026-02-17 | — | — | US | claimed |
| EP-4147053-B1 | ANTXR1 AS A BIOMARKER OF IMMUNOSUPPRESSIVE FIBROBLAST POPULATIONS AND ITS USE FOR PREDICTING RESPONSE TO IMMUNOTHERAPY | INST CURIE (FR) | 2026-01-28 | — | — | EP | claimed |
| US-20260021107-A1 | STIMULATOR OF INTERFERON GENES AGONISTS | INIMMUNE CORP (US) | 2026-01-22 | — | — | US | claimed |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | OTSUKA PHARMA CO LTD (JP) | 2026-01-01 | — | — | US | claimed |
| EP-2315756-B1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2014-09-03 | — | — | EP | claimed |
| US-8822511-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-09-02 | — | — | US | claimed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | claimed |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION (US) | 2014-01-23 | — | — | US | claimed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | claimed |
| US-8088803-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| JP-2011527686-A | — | — | 2011-11-04 | — | — | JP | claimed |
| EP-2315756-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2011-05-04 | — | — | EP | claimed |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION | 2010-01-21 | — | — | US | claimed |
| WO-2010005958-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2010-01-14 | — | — | WO | claimed |